Company Filing History:

7 out of 3,840

Imperial Chemical Industries Limited

National Research Development Corporation

patents

where one patent can have more than one assignee

Years Active: 1989-2004

Loading Chart...

13 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 6787562 - Substituted aryl and heteroaryl compounds as E-type prostaglandin antagonists (2004-09-07),

2. 6057345 - Substituted aryl and heteroaryl compounds as E-type prostaglandin (2000-05-02),

3. 5965741 - Ortho-substituted aromatic ether compounds and their use in (1999-10-12),

4. 5843942 - Aromatic amino ethers as pain relieving agents (1998-12-01),

5. 5834468 - Substituted aryl and heteroaryl compounds as E-type prostaglandin (1998-11-10),

6. 5811459 - Ortho substituted aromatic compounds useful as antagonists of the pain (1998-09-22),

7. 5395838 - 6-substituted quinazolines processing anti-tumor activity (1995-03-07),

8. 5317101 - Tricyclic heterocycles (1994-05-31),

9. 5252573 - Anti-tumor agents (1993-10-12),

10. 5089499 - Quinazoline derivatives possessing anti-tumor activity (1992-02-18),

11. 5032592 - Alkene, alkyne or cycloalkylene derivatives (1991-07-16),

12. 4985441 - Anti-tumor agents (1991-01-15),

13. 4873329 - Alkene, alkyne or cycloalkylene derivatives (1989-10-10),

Title: John Oldfield: A Pioneer in Pharmaceutical Innovation

Introduction

John Oldfield, an accomplished inventor based in Wilmslow, GB, has made significant contributions to the field of pharmaceuticals. With a remarkable portfolio of 13 patents, he has focused on developing compounds that play a crucial role in managing pain.

Latest Patents

Among his notable inventions are his latest patents on substituted aryl and heteroaryl compounds, which serve as E-type prostaglandin antagonists. These compounds, along with their pharmaceutically acceptable salts, are designed to counteract the pain-enhancing effects of E-type prostaglandins. The patents convey important processes for the preparation of these compounds, as well as pharmaceutical compositions that integrate these innovative substances. Furthermore, they outline methods for treating pain through the administration of these newly developed compounds.

Career Highlights

Throughout his career, Oldfield has been associated with prestigious companies, including Imperial Chemical Industries Limited and Zeneca Limited. His work has often been at the intersection of chemistry and medicine, leading to cutting-edge advancements that have practical applications in therapeutic settings.

Collaborations

In his pursuit of innovation, John Oldfield has collaborated with notable colleagues, such as Howard Tucker and Leslie R Hughes. These partnerships have likely contributed to the depth and breadth of his research and patent submissions, fostering a creative environment that encourages both individual and collective achievements.

Conclusion

John Oldfield's journey as an inventor exemplifies a commitment to advancing pharmaceutical science. His numerous patents not only highlight his innovative spirit but also demonstrate the tangible impact of his work on pain management. As he continues to contribute to the field, his legacy as a pioneer in pharmaceutical innovation is firmly established.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com